Cancer 
Management:
 A Multidisciplinary 
Approach

Article

The information in this volume has been carefully reviewed for accuracy of dosage and indications. Before prescribing any drug, however, the clinician should consult the manufacturer’s current package labeling for accepted indications, absolute dosage recommendations, and other information pertinent to the safe and effective use of the product described.

Edited byRichard Pazdur, MD
Director, Office of Oncology Drug Products?
Center for Drug Evaluation and Research?
US Food and Drug Administration

Lawrence D. Wagman, MD
Executive Medical Director
The Center for Cancer Prevention and Treatment?
St. Joseph Hospital

Kevin A. Camphausen, MD
Chief, Radiation Oncology Branch?
National Cancer Institute

William J. Hoskins, MD
Executive Director of Surgical Activities?
Memorial Sloan-Kettering Cancer Center

?And the publishers of the journal ONCOLOGY Note to the reader
The information in this volume has been carefully reviewed for accuracy of dosage and indications. Before prescribing any drug, however, the clinician should consult the manufacturer’s current package labeling for accepted indications, absolute dosage recommendations, and other information pertinent to the safe and effective use of the product described. This is especially important when drugs are given in combination or as an adjunct to other forms of therapy. Furthermore, some of the medications described herein, as well as some of the indications mentioned, had not been approved by the US Food and Drug Administration at the time of publication. This possibility should be borne in mind before prescribing or recommending any drug or regimen.

Copyright © 2009 by CMP Healthcare Media LLC. All rights reserved. This book is protected by copyright. No part of it may be reproduced in any manner or by any means, electronic or mechanical, without the written permission of the publisher.

 

The views expressed are the result of independent work and do not necessarily represent the views or findings of the US Food and Drug Administration or the United States.

 

Library of Congress Catalog Card Number 2009939446
ISBN Number 9781891483639

For information on purchasing additional copies of this publication, visit www.cancernetwork.com/cancer-management or contact Michael Krager, Sr. Circulation Manager, by e-mail, subscriptions@cmpmedica.com, or by mail, addressed to UBM Medica, Attention Michael Krager, 535 Connecticut Avenue, Suite 300, Norwalk, CT 06854. Telephone: 203.523.7036; Fax: 203.842.0885.

 

Publishers of

ONCOLOGY
ONCOLOGY Nurse Edition
Oncology News International
cancernetwork.com

Recent Videos
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
Related Content